Inactive Instrument

News Antibe Therapeutics Inc Toronto S.E.

Equities

ATE

CA0370251039

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Antibe Announces Appointment of Receiver	04-24	BU
Antibe Therapeutics Inc. Announces Board Resignations	04-24	CI
ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS	04-22	AQ
Antibe Therapeutics Seeks Extension of Stay of Proceedings	04-19	MT
Antibe Provides Update on CCAA Proceedings	04-19	BU
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	04-16	MT
Antibe Therapeutics Brief: Announcing TSX Delisting Review	04-16	MT
Antibe Announces TSX Delisting Review	04-16	BU
ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT	04-10	AQ
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act	04-09	BU
DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE	04-09	AQ
Canadian Investment Regulatory Organization Trading Halt - ATE	04-09	AQ
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act	04-09	BU
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	04-09	MT
Antibe Therapeutics Inc. Announces Board Resignations	04-09	CI
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	04-01	DJ
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	04-01	DJ
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Antibe Therapeutics Inc Toronto S.E.

Equities

ATE

CA0370251039

Summary

Filters